1,068 results on '"Dougan, Michael"'
Search Results
102. Immunotherapy of Cancer
103. Abstract C082: Signaling pathways inducing tumoricidal phagocytosis in pancreatic cancer
104. Abstract B018: Eosinophils alter metastatic spread in pancreatic cancer
105. 1004 Signaling pathways inducing tumoricidal phagocytosis in pancreatic cancer
106. The association between non-English primary language and COVID-19 clinical trial eligibility and enrollment: A retrospective cohort study
107. 1242 Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define checkpoint inhibitor colitis
108. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
109. Monoclonal antibodies for the treatment of COVID-19 infection in children
110. The primacy of Union law over incompatible national measures: Beyond disapplication and towards a remedy of nullity?
111. S720 Endoscopic Severity Score of Immune-Mediated Colitis Is More Effective in Guiding Medical Treatment Than Clinical Severity Grade
112. Human differentiated eosinophils release IL-13 in response to IL-33 stimulation
113. Monoclonal Antibodies
114. Programmable bacteria as cancer therapy
115. The UK’s Institutional Balance of Power After Leaving the EU
116. Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis.
117. Case 14-2022: A 57-Year-Old Man with Chylous Ascites
118. IFNγ from IL-12 virotherapy stably controls tumors independent of T cell cytotoxicity and IFNγ sensing by tumor cells
119. 375: CONCURRENT IMMUNE CHECKPOINT INHIBITION AND SELECTIVE IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH IMMUNE-RELATED ENTEROCOLITIS
120. Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy
121. Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of Covid-19 Patients Treated with Intravenous Infusion or Subcutaneous Injection
122. Progressive chronic kidney function decline as a clinical presentation of immune checkpoint inhibitor-associated nephrotoxicity
123. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
124. Targeted MR contrast nanoparticles for Programmed Death Ligand-1 expression
125. Sa1198 CELLULAR AND MOLECULAR PROFILING OF COLLAGENOUS GASTRITIS FOR NOVEL THERAPEUTIC OPTIONS
126. Mo1356 THE DEVELOPMENT OF POST-INFLAMMATORY GASTROINTESTINAL SYMPTOMS IN PATIENTS WHO HAVE HAD AN IMMUNE CHECKPOINT INHIBITOR-RELATED ADVERSE EVENT IN THE GASTROINTESTINAL TRACT
127. Engineering T cell memory for antitumor immunity
128. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
129. From the EU Single Market to the UK Internal Market: Practice Doesn't Always Make Perfect …
130. The Landscape of COVID-19 Research in the United States: a Cross-sectional Study of Randomized Trials Registered on ClinicalTrials.Gov
131. Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
132. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
133. First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
134. Tissue eosinophils express the IL‐33 receptor ST2 and type 2 cytokines in patients with eosinophilic esophagitis
135. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
136. Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed
137. Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors
138. Antigen identification and high-throughput interaction mapping by reprogramming viral entry
139. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
140. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
141. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
142. Dardanelle and the Bottoms: Environment, Agriculture, and Economy in an Arkansas River Community, 1819–1970 Gleason Mildred Diane
143. The UK’s withdrawal from the EU : a legal analysis
144. A dual role for the immune response in a mouse model of inflammationassociated lung cancer
145. Legal Developments
146. The EU’s duty to respect hungarian sovereignty: An action plan
147. Editorial: A special issue in honour of Alison McDonnell: basso continuo of the Common Market Law Review
148. Legal Developments
149. Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
150. A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.